|
|
Article: Circassia Achieves Successful Phase II Clinical Results With Toleromune Anti-Allergy Technology.
- Article from:
- Clinical Trials Week
- Article date:
- September 22, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Circassia Ltd, a specialty biopharmaceutical company focused on
controlling immune system responses, announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients (see also Circassia Ltd).
Circassia conducted the double-blind study in Germany, where patients with a confirmed history of cat allergies received a single dose of ToleroMune therapy or placebo. The 88 study participants were divided into ...
Related newspaper, magazine, and journal articles:
|
|
Article: Circassia Announces the Appointment of Sir Richard Sykes ...
PR Newswire;
July 4, 2007 ;
700+ words
... ... England, July 4 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company ... year. Mr Swingland will remain with Circassia as Deputy Chairman and General Counsel ... during this period of exciting growth for Circassia," said Charles Swingland, Circassia ...
|
|